Yi Wang

Prof. Yi Wang


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2017 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ZFZiling Fang
Ziling Fang
LZLing Zhang
Ling Zhang
QLQuan Liao
Quan Liao
YWYi Wang
Yi Wang
FYFeng Yu
Feng Yu
JXJianping Xiong
Jianping Xiong
Increasing evidence highlights the important roles of tripartite motif containing 24 (TRIM24) in tumor initiation and malignant progression in many tumors, including gastric cancer (GC). Although TRIM24 expression is remarkably upregulated during GC carcinogenesis, the molecular mechanisms underlying TRIM24 dysregulation remain unexplored. In this study, miRNA target prediction tools were applied to explore miRNAs that potentially target TRIM24. Western blot and quantitative reverse-transcriptase PCR (qRT-PCR) were performed to detected TRIM24 and miR-511 expression in GC tissues and cell lines. Dual-luciferase reporter assay was utilized to validate if TRIM24 is a direct target gene of miR-511. CCK-8 assay, cell colony formation assay, EdU incorporation assay and cell cycle analysis were performed to determine whether miR-511-mediated regulation of TRIM24 could affect GC progression. In our study, miR-511 was found to be downregulated in GC and an inverse correlation was observed between TRIM24 and miR-511 expression in primary GC tissues and cell lines. Dual-luciferase reporter assay further verified TRIM24 is a direct target of miR-511. Functional assays showed miR-511 overexpression inhibited cell growth, colony formation ability and cell cycle progression. Conversely, inhibition of endogenous miR-511 promoted these phenotypes in GC cells. Moreover, reintroduction of TRIM24 rescued miR-511-induced inhibitory effects on GC cells. Furthermore, miR-511 elicits tumor-suppressive effects through inactivating PI3K/AKT and Wnt/β-catenin pathways by suppressing TRIM24. Our results provide the new evidence supporting the tumor-suppressive role of miR-511 in GC by suppressing TRIM24, suggesting that this novel miR-511/TRIM24 axis is critical in the control of gastric cancer tumorigenesis.

19 March 2024 in Vascular
Verified
Journal Article
Closed access
QXQiyang Xu
Qiyang Xu
YWYi Wang
Yi Wang
BXBin Xu
Bin Xu
DLDehai Lang
Dehai Lang
ZLZuodong Lin
Zuodong Lin
Objective: Acute superior mesenteric artery embolism is a life-threatening disease caused by the abrupt interruption of mesenteric blood circulation, and the prognosis is very poor. Several studies have confirmed the efficacy and safety of percutaneous mechanical thrombectomy in acute superior mesenteric artery embolism, however, there are currently no literature reports on the latest percutaneous mechanical thrombectomy device—AcoStream™. In the present report, we summarize a series of cases and share our surgical experiences. Methods: The clinical data of 10 patients (six men and four women, mean age 77.6 ± 7.4 years) with acute superior mesenteric artery embolism treated by AcoStream™ in our center from December 2022 to December 2023 were retrospectively analyzed. Based on the literature, we summarized the diagnosis, therapy, and surgical experience of acute superior mesenteric artery embolism. Results: Percutaneous mechanical thrombectomy was performed for all the patients. The success rate of surgery reached 100% and no perioperative complications occurred. Abdominal pain was significantly relieved and the abdominal signs gradually disappeared in eight patients, while the other two patients still complained of abdominal pain during hospitalization, and eventually, they underwent resection of necrotic bowel. All the patients’ symptoms were significantly relieved and they were smoothly discharged from the hospital. Conclusions: As shown in the present study, percutaneous mechanical thrombectomy using AcoStream™ is minimally invasive, safe, and efficient in the initial stage of acute superior mesenteric artery embolism. We believe that percutaneous mechanical thrombectomy can be a promising alternative in selected cases.

18 January 2023 in Indian Journal of Surgery
Verified
Journal Article
Closed access
PDF file
QXQiyang Xu
Qiyang Xu
YWYi Wang
Yi Wang
BXBin Xu
Bin Xu
DLDehai Lang
Dehai Lang

29 April 2026 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
YWYi Wang
Yi Wang
JXJianfen Xu
Jianfen Xu
LLLinchun Liang
Linchun Liang
YCYunjie Chen
Yunjie Chen
LFLeizheng Fei
Leizheng Fei
CRChuangzhou Rao
Chuangzhou Rao
Both fruquintinib and TAS‐102 monotherapies are guideline‐recommended for third‐line treatment of metastatic colorectal cancer (mCRC). This study aimed to analyze the preliminary outcomes of fruquintinib combined with TAS‐102, with or without stereotactic body radiation therapy (SBRT), as a third‐ or later‐line therapy for mCRC. This prospective, two‐arm, phase II study planned to enroll 66 patients with mCRC who were unresponsive to at least two prior lines of therapy. Patients were allocated to either the FTS (fruquintinib + TAS‐102 + SBRT) or FT (fruquintinib + TAS‐102) group. Eligible patients received fruquintinib (4 mg, qd, days 1–21) and TAS‐102 (30 mg/m 2 , bid, days 1–5; 15–19) orally every 4 weeks until disease progression or intolerable toxicity. The primary endpoint was progression‐free survival (PFS, per RECIST 1.1); secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs, graded using CTCAE v5.0). By January 20, 2025, 40 patients were enrolled (FTS group, 11; FT group, 29), with a median follow‐up of 8.48 months. In 20 (50%) patients, the number of metastatic organs was ≥ 3. However, the number of metastatic lesions was > 5 in 32 (80%) patients. For the 36 eligible patients, the ORR and DCR were 19.4% and 88.9%, respectively. The median PFS was 8.58 months; however, the median OS has not been attained. The most common treatment‐related AE was decreased white blood cell count (92.5%); grade 3–4 AEs included decreased lymphocyte count (12.5%). No treatment‐related death occurred. Fruquintinib combined with TAS‐102, with or without SBRT, showed promising preliminary efficacy and acceptable safety as third‐ or later‐line treatment of mCRC.